International Stem Cell Corporation to Host Second Quarter 2012 Financial Results Conference Call at 11:00 am ET on …

CARLSBAD, CA--(Marketwire -08/08/12)- International Stem Cell Corporation (ISCO) http://www.internationalstemcell.com, a California-based biotechnology company focused on therapeutic and research products, announced today that it will host a conference call on Friday, August 10, 2012 at 11:00 am ET to discuss its financial results for the three months ended June 30, 2012.

Dr. Simon Craw, Executive Vice President of Business Development, and Ms. Linh Nguyen, Chief Financial Officer, will host the conference call.

To attend the call, please use the dial in information below:

Date: Friday, August 10, 2012 Time: 11:00 am Eastern Time Conference Line (U.S.): 1-877-317-6776 International Dial-In: 1-412-317-6776 Conference ID: 10017300 Webcast: http://webcast.mzvaluemonitor.com/Home/Login/7fd6c4da-37f0-472c-9f28-cd9eb1b99f87

Please dial in at least 10-minutes before the call to ensure timely participation.

A playback replay of the conference call will be available for two weeks following 1 hour after the end of the conference call through end date: Aug 24, 2012 at 9:00 am ET.

Teleconference Replay Details:

US Domestic: 1-877-344-7529 International: 1-412-317-0088 Conference ID: 10017300

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com or follow us on Twitter @intlstemcell.

See more here:
International Stem Cell Corporation to Host Second Quarter 2012 Financial Results Conference Call at 11:00 am ET on ...